ArticleOncogene2008
Cyclin D3 action in androgen receptor regulation and prostate cancer.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- PCB Exposure in Adult Male Mice Reduces Proliferating Cells in the Prostate but Minimally Alters Voiding.Toxics · 2026Article
- Cisplatin-mediated activation of NF-κB promotes lung cancer stem cell formation via DNA repair pathways.Journal of translational medicine · 2025Article
- Article
- CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia.Oncogenesis · 2022Article
- Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG human glioblastoma cells.Oncotarget · 2022Article
- Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder.Molecular oncology · 2021Article
- Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis.Cancer cell international · 2019Review
- Lack of cyclin D3 induces skeletal muscle fiber-type shifting, increased endurance performance and hypermetabolism.Scientific reports · 2018Article
- Caspase-2: the reinvented enzyme.Oncogene · 2015Review
- Article
- The AR dependent cell cycle: mechanisms and cancer relevance.Molecular and cellular endocrinology · 2012Review
- Viral cyclins mediate separate phases of infection by integrating functions of distinct mammalian cyclins.PLoS pathogens · 2012Article
- Caspase-2-Based Regulation of the Androgen Receptor and Cell Cycle in the Prostate Cancer Cell Line LNCaP.Genes & cancer · 2011Article
- Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.The Journal of biological chemistry · 2011Article
- Requirement for cyclin D3 in germinal center formation and function.Cell research · 2010Article
- The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.Journal of cellular and molecular medicine · 2009Article
- Article
- Article
- Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.Journal of the American Medical Informatics Association : JAMIAArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Prostate cancer (PCa) cell proliferation is dependent on activation of the androgen receptor (AR), a ligand-dependent transcription factor. AR activation controls G1-S phase progression through fostering enhanced translation of the D-type cyclins, which promote cell cycle progression through activation of CDK4/6. However, the D-type cyclins harbor additional, CDK4/6 kinase-independent, functions through manipulation of transcription factors, including AR. It was previously established that cyclins D1 and D3 have the potential to modulate AR, and with regard to cyclin D1, disruption of this function occurs in human tumors. Therefore, it was essential to interrogate cyclin D3 function in this tumor type. Here, we show that cyclin D3 is found in association with AR in PCa cells, as mediated through a conserved motif. Cyclin D3 functions to attenuate AR activity through defined mechanisms that include modulation of ligand-dependent conformational changes and modulation of chromatin binding activity. Accumulated cyclin D3 slows cell proliferation in AR-dependent cells, thus suggesting that androgen-induced D-type cyclin production serves to temper the mitogenic response to androgen. Supporting this hypothesis, it is shown that cyclin D3 expression is reduced in primary PCas as a function of tumor grade, and inversely correlates with the proliferative index. In total, these data identify cyclin D3 as a critical modulator of the androgen response, whose deregulation may foster unchecked AR activity in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.